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aBsTRacT
INTRODUCTION: Lung cancer remains a leading cause of 
cancer-related death. The incidence increases with age and 
the occurrence in young patients is relatively low. The clin-
icopathological features of lung cancer in younger patients 
have not been fully explored previously. 
METHODS: To assess the age differences in the clinical char-
acteristics of lung cancer, we conducted a retrospective 
analysis comparing young patients ≤ 65 years of age with an 
elderly group > 65 years of age.  Among 1,232 patients 
evalu ated due to suspicion of lung cancer in our fast-track 
setting from January-December 2013, 312 newly diagnosed 
lung cancer patients were included.
RESULTS: Patients ≤ 65 years had a significantly higher rep-
resentation of females (p = 0.0021), more frequent familial 
cancer aggregation (p = 0.028) and a lower incidence of 
squamous cell carcinoma (p = 0.0133). When excluding pure 
carcinoid tumours, a significantly higher proportion of the 
younger patients presented with advanced stage disease  
(p = 0.0392). Combined modality therapy was more com-
mon in younger patients (p = 0.0009), while chemotherapy 
appeared less prevalent among the elderly (p = 0.0015). 
CONCLUSIONS: Lung cancer in younger patients comprises a 
distinct clinicopathological entity with more frequent ad-
vanced stage disease and a significantly greater proportion 
with a family history of cancer. Implementing genetic back-
ground assessments and considering lung cancer as a pos-
sible diagnosis in younger, symptomatic patients, is of para-
mount importance. 
FUNDING: none. 
TRIAL REGISTRATION: The study was approved by the 
 Danish Data Protection Agency. 
Lung cancer is among the most common malignancies 
worldwide. In 2012, the death rate from lung cancer al-
most reached the combined mortality from breast, pros-
tate and colon cancer [1]. Lung cancer has an overall 
five-year survival of 17%; however, when diagnosed in 
early stages, it is possible to offer treatment with a cura-
tive intent which raises the five-year survival to > 50% 
[2].
Lung cancer typically affects elderly individuals. 
Approximately two out of three patients diagnosed with 
lung cancer are 65 years or older; fewer than 2% of all 
cases are found in patients younger than 45 years of  
age [1]. The average age at diagnosis is about 70 years 
[1].
As our clinical impression is that younger patients 
present in more advanced stages, we conducted a retro-
spective analysis to examine the clinical characteristics 
and management of a cohort of newly diagnosed lung 
cancer patients. 
mEThOds
The medical records of patients referred for evaluation 
of suspected lung cancer at Vejle Hospital in 2013 were 
reviewed for epidemiologic data and clinical history. 
During this period, 1,232 patients were evaluated in our 
fast-track setting, and in 332 patients the diagnosis was 
confirmed. 
The following parameters were extracted and ana-
lysed: age, gender, smoking habits, occupational/envir-
onmental exposure to asbestos, previous cancer, self- 
reported familial history of cancer, symptoms, perform-
ance status (PS) as defined by the Eastern Cooperative 
Oncology Group [3], clinical stage, cytological/histo-
logical subtype, diagnostic procedures and treatment. 
Cyto-histopathology was categorised according to the 
World Health Organization classification of lung tu-
mours, whereas clinical staging was based upon the  
international tumour-node-metastasis system as defined 
in the seventh edition by the The International Union 
Against Cancer in 2010 [4].
Patients with intrathoracic metastases from ex-
trapulmonary cancer (n = 1) without unambiguous clin-
ical staging or sufficient biopsy verification (n = 19) were 
excluded from the analysis. Eligible patients were cate-
gorised into four groups according to age: ≤ 55 years, 
56-65 years, 66-75 years and finally > 75 years (Table 1, 
Table 2 and Table 3). 
Statistical analyses were performed on combined 
age groups, comparing the clinicopathological features 
of patients ≤ 65 years (defined in the following as  
younger patients) with patients > 65 years (defined in 
the following as elderly patients). 
We conducted all statistical analyses using 2 × 2 
contingency tables in GraphPad software. 
p-values were calculated by Fisher’s two-tailed ex-
act test due to low numbers in some calculations when 
absolute numbers were compared. Welch’s t-test was 
utilised for mean value comparisons. 
Trial registration: The study was approved by the Danish 
Data Protection Agency. 
lung cancer in younger patients
Leda Abbasowa1 & Poul Henning Madsen2
ORiginal 
aRTiclE
1) Department of 
Neurology, Odense 
University Hospital
2) Department of 
Medicine, Division of 
Respiratory Medicine, 
Vejle Hospital, 
Denmark
  
Dan Med J 
2016;63(7):A5248
 2  da n i s h m E d i c a l J O U R n a l Dan Med J 63/7  July 2016
REsUlTs
demographic data 
The final retrospective study sample included data on 
312 patients. Their age ranged from 21-93 years with a 
median age of 69 years. Female patients were slightly 
overrepresented, and the highest female-to-male ratio 
(1.7) was found in the youngest age group (Table 1). 
Most patients (93.6%) were current or ex-smokers 
with a mean cumulative tobacco consumption of 43.2 
pack-years (range: 2-252 pack-years). There were no  
differences between male and female smokers in the 
two age groups (p = 0.4808 for patients ≤ 65 years; p = 
0.2249 for patients > 65 years). In 37 patients (11.9%), 
exposure to asbestos was recorded, whereas 97 medical 
records failed to address this issue. No significant age 
differences were found (Table 1). 
A total of 115 patients (36.9%) presented a family 
history of cancer. Familial cancer accumulation proved 
considerably more prevalent among the younger lung 
cancer patients (p = 0.028 for any family history of can-
cer, p = 0.0026 for a family history of lung cancer and  
p < 0.0001 for ≥ 1 first-degree relative with lung cancer, 
respectively) (Table 1, Figure 1A).  
symptoms 
Symptoms were similar in both age groups (Table 1) and 
included: persistent cough (50%), dyspnoea (34.6%), 
weight loss (31.4%), pain (most commonly in the chest, 
shoulder and abdomen) (28.5%) and chronic fatigue 
(21.8%). Less frequently reported symptoms were 
haemoptysis (11.5%), fever/recurring pneumonia 
(10.6%), nocturnal sweating (9.6%) and neurological 
complaints (16.7%). There were no statistically signifi-
cant age differences in the duration of predominant 
symptoms (Table 1).
Of the 312 patients included, 45 (14.4%) were 
asymptomatic (Table 1). In these patients, lung cancer 
was primarily discovered as an unsuspected incidental 
finding on a chest X-ray/computed tomography (CT) dur-
ing routine medical check-up. 
diagnostic procedures 
Diagnostic procedures were overall comparable across 
the age groups. The majority of patients (99.7%) under-
went CT of the chest and abdomen, whereas 91.7% had 
positron emission tomography (PET)/CTs performed  
(Table 2). 
TaBlE 1
Base-line characteristics 
and symptoms.
age, yrs
≤ 55 56-65 66-75 > 75 p-valuea
Base-line characteristics
Patients, n (%) 29 (9.2) 82 (26.3) 121 (38.8) 80 (25.6) < 0.0001
Males, n (%) 10 (34.5) 31 (37.8) 66 (54.5) 45 (56.3) 0.0021
Current or former smoker, n (%) 26 (89.7) 76 (92.7) 115 (95) 75 (93.8) 0.4693
Smoking, pack-years,  n, mean [range] 32.5 [3-95] 38.8 [2-150] 48.2 [3-252] 43.9 [10-130] 0.0019
Asbestos exposure, n (%) 2 (6.9) 9 (11) 16 (13.2) 10 (12.5) 0.4700
Family history of cancer, n (%) 13 (44.8) 37 (45.1) 44 (36.4) 21 (26.3) 0.028
Family history of lung cancer,  n (%) 8 (27.6) 15 (18.3) 12 (9.9) 5 (6.3) 0.0026
Family history of ≥ 1 1st-degree relative with lung cancer, n (%) 4 (13.8) 14 (17.1) 11 (9.1) 4 (5) < 0.0001
Previous cancer, n (%) 3 (10.3) 15 (18.3) 27 (22.3) 19 (23.8) 0.1885
WHO performance status ≤ 2, n (%) 29 (100) 79 (96.3) 115 (95) 70 (87.5) 0.0827
FEV1, % predicted 79.3 72.4 68.9 70.5 0.0358
COPD, n (%) 10 (35.7) 42 (53.8) 69 (62.2) 50 (64.9) 0.0433
Symptoms
Duration of predominant symptom, weeks, mean [range] 19.7 [1-114] 13.7 [1-96] 22.2 [1-720] 14.5 [1-58] 0.2097
Haemoptysis, n (%) 2 (6.9) 9 (11) 14 (11.6) 11 (13.8) 0.5813
Pain, n (%) 17 (58.6) 22 (26.8) 39 (32.2) 11 (13.8) 0.0666
Dyspnoea, n (%) 12 (41.4) 26 (31.7) 44 (36.4) 26 (32.5) 1.0000
Cough, n (%) 19 (65.5) 40 (48.8) 61 (50.4) 35 (43.8) 0.4081
Weight loss, n (%) 8 (27.6) 20 (24.4) 40 (33.1) 30 (37.5) 0.0976
Chronic fatigue, n (%) 7 (24.1) 12 (14.6) 28 (23.1) 21 (26.3) 0.1535
Night sweats, n (%) 4 (13.8) 10 (12.2) 13 (10.7) 3 (3.8) 0.2284
Fever/unresolving pneumonia, n (%) 5 (17.2) 7 (8.5) 13 (10.7) 8 (10) 1.0000
Neurologic symptoms, n (%) 7 (24.1) 13 (15.9) 20 (16.5) 12 (15) 0.6372
Asymptomatic, n (%) 2 (6.9) 12 (14.6) 16 (13.2) 15 (18.8) 0.2141
COPD = chronic obstructive pulmonary disease; FEV1 = forced expired volume in the 1st sec. 
a) ≤ 65 vs > 65 yrs.  
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Histopathology and/or cytopathology specimens 
were obtained via bronchoscopy (74.4%), endobronchial 
ultrasound/endoscopic ultrasound (74%), thoracoscopy 
(3.5%), mediastinascopy (1.6%) and CT-guided percu-
taneous needle biopsies (42.6%). 
Additional invasive procedures included gland extir-
pation and biopsies from suspected distant metastatic 
lesions (19.2%). 
Several patients underwent multiple invasive inves-
tigations.
 lung cancer subtypes 
Adenocarcinoma comprised 53.2% of all lung cancers of 
a defined histological subtype, followed by squamous-
cell carcinoma (24.7%) and small-cell lung carcinoma 
(18.6%). Squamous cell carcinoma was less frequent in 
the younger population (p = 0.0133; Table 2). 
stages 
The majority of patients had advanced stage disease (III-
IV) at presentation (69.2%), while local-stage disease (I-II) 
was found in 96 patients (30.8%). When excluding pati-
ents with pure carcinoid tumours from the statistical 
analyses, a significantly higher proportion of the younger 
patients had advanced, non-resectable disease at diagno-
sis (p = 0.0392) (Figure 1B). As depicted in Table 2, 82.1% 
of the youngest patients presented with advanced stage, 
while this was the case in 66.3% of the oldest patients.  
Treatment 
Surgery was performed in 62 patients (19.9%). Four dif-
ferent surgical approaches were utilised:  lobectomy (ac-
counting for 67.7% of all operations), followed by seg-
ment/wedge resection (25.8%) and pneumonectomy 
(6.5%). 
TaBlE 2
 
age, yrs
≤ 55 56-65 66-75 > 75 p-valuea
Patients 29 (9.2) 82 (26.3) 121 (38.8) 80 (25.6) < 0.0001
Diagnosis
Adenocarcinoma 17 (58.6) 48 (58.5)   64 (52.9) 36 (45) 0.1555
Squmaous cell carcinoma   3 (10.3) 15 (18.3)   28 (23.1) 30 (37.5) 0.0133
Small cell carcinoma   6 (20.7) 14 (17.1)   26 (21.5) 13 (16.3) 0.8801
Large cell carcinoma   0 (0)   3 (3.7)     1 (0.8)   0 (0) 0.1306
Other, undifferentiated or mixed tumour   3 (10.3)   2 (2.4)     2 (1.7)   1 (1.3) 0.1381
EGFR mutation   1 (3.4)   2 (2.4)     4 (3.3)   3 (3.8) 1.0000
Overall clinical stage
IA   4 (13.8)   5 (6.1)   13 (10.7) 10 (12.5) 0.4373
IB   0 (0)   5 (6.1)   10 (8.3)   6 (7.5) 0.3457
IIA   1 (3.4)   6 (7.3)     7 (5.8)   3 (3.8) 0.6118
IIB   1 (3.4)   3 (3.7)     7 (5.8)   7 (8.8) 0.3118
IIIA   4 (13.8) 16 (19.5)   23 (19) 13 (16.3) 0.2451
IIIB   6 (20.7)   9 (11)     9 (7.4) 12 (15) 0.4607
IIII 13 (44.8) 38 (46.3)   52 (43) 28 (35) 0.3380
T1-3 and N0-1 and M0: resectable stages   6 (20.7) 21 (25.6)   42 (34.7) 27 (33.8) 0.0736
T4 or N2-3 or M1: unrectable stages 23 (79.3) 61 (74.4)   79 (65.3) 53 (66.3) 0.0736
T1-3 and N0-1 and M0: resectable stages, excl. pure carcinoids   5 (17.9) 20 (24.7)   42 (34.7) 27 (33.8) 0.0392
T4 or N2-3 or M1: unrectable stages, excl. pure carcinoids 23 (82.1) 61 (74.3)   79 (65.3) 53 (66.3) 0.0392
Diagnostic modality
CT chest and abdomen 29 (100) 82 (100) 120 (99.2) 80 (100) 1.0000
PET/CT 27 (93.1) 69 (84.1) 115 (95) 75 (93.8) 1.0000
Other, e.g. bone scan and brain imaging   8 (27.6) 25 (30.5)   28 (23.1) 14 (17.5) 0.0967
Bronchoscopy 20 (69) 56 (68.3)   93 (76.9) 63 (78.8) 0.1040
EBUS/EUS 21 (72.4) 57 (69.5)   91 (75.2) 62 (77.5) 0.2818
Biopsy from distant metastasis   9 (31) 21 (25.6)   19 (15.7) 11 (13.8) 0.0110
CT-guided biopsy   8 (27.6) 29 (35.4)   56 (46.3) 40 (50) 0.0852
Thoracocentesis   0 (0)   5 (6.1)     7 (5.8)   3 (3.8) 1.0000
Surgical lung biopsy   1 (3.4)   2 (2.4)     3 (2.5)   5 (6.3) 0.7521
Mediastinoscopy   0 (0)   4 (4.9)     0 (0)   1 (1.3) 0.0558
CT = computed tomography; EBUS/EUS = endobronchial ultrasound/endoscopic ultrasound; EGFR = epidermal growth factor receptor;  
PET = positron emission tomography. 
a) ≤ 65 vs > 65 yrs.
Diagnosis, overall clinical 
stage and use of diagnos-
tic modalities. The values 
are n (%).
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Other treatment modalities included radiotherapy 
(57.4%) and various chemotherapy regimens (67.9%). 
Combined-modality therapy was administered in 159 
patients (51%) and was significantly more frequent in 
the younger patients (p = 0.0009) (Table 3). 
A total of 22 patients (7.1%) had no active treat-
ment. Reasons for not receiving treatment included low 
PS/comorbidities (n = 10), post-biopsy complications  
(n = 1), early death before initiation of planned therapy 
(n = 5) or refusal of treatment (n = 6). 
discUssiOn
In comparison to younger patients we found the inci-
dence of squamous cell carcinoma to be significantly 
higher in the elderly (Table 2). Squamous cell carcinoma 
is epidemiologically more closely associated with smok-
ing than adenocarcinoma [5]. This is peculiar considering 
that the proportion of smokers was similar for the two 
age groups and genders (Table 1). However, elderly pa-
tients had a higher accumulated smoking history than 
younger patients, which can explain this finding. Also, it 
is reasonable to assume that the consumption of high-
tar unfiltered cigarettes was higher in this more ad-
vanced age category. Since adenocarcinoma appears to 
be more prevalent in women [6], another possible ex-
plan ation for the higher percentage of squamous cell 
carcinoma in the elderly could be the skewed gender 
distribution including a significantly higher female-to-
male ratio in the younger population. 
Finally, as patients ≤ 65 years presented with a 
higher number of familial cancer incidences, genetic pre-
disposition rendering younger individuals more suscept-
ible to lung cancer development could also offer a possi-
ble explanation as to why adenocarcinoma was the 
leading cell type in younger patients, whereas squamous 
cell carcinoma proved more common among the elderly. 
Even after adjusting for smoking habits, several epi-
demiologic and clinical studies have identified familial 
aggregation of lung cancer, particularly in families with 
adenocarcinoma [7-9]. Furthermore, a large proportion 
of early-onset lung cancers (< 50 years at diagnosis) ap-
pears to be heritable, suggesting that the risk due to cig-
arette smoking is further amplified by genetic factors 
[8]. Increasing evidence has shown that genes coding for 
carcinogen metabolism and DNA repair contribute sig-
nificantly to familial clustering of lung cancer [10, 11].
Although in our study genetic background appears 
to be a preponderant factor, one must also consider the 
possibility of recall bias. Younger patients have a more 
recent memory of familial cancer than older patients do, 
and since cancer today is diagnosed in later stages of life 
than previously, the parents of elderly patients may very 
well have had undiagnosed cancer. 
When comparing the two age categories the per-
centage of patients with non-resectable, advanced-stage 
disease was significantly higher in the younger group 
provided that a small subset of patients with pure car-
cin oid tumours was excluded from the statistical ana-
lyses (Figure 1B). This exclusion seemed reasonable 
since typical low-grade malignant carcinoid tumours 
comprise a rare and distinct spectrum of pathological, 
epidemiological, clinical and prognostic features and are 
often perceived as a separate biological entity [12]. Even 
when calculations incorporated all patients, including 
the two carcinoid cases, a clear-cut trend towards statis-
FigURE 1
a. Phenotypic genetics: The differences between the younger patients ≤ 
65 years and elderly patients > 65 years are statistically significant with  
p-values of 0.028, 0.0026 and < 0.0001 for family history of any cancer , 
family history of lung cancer  and for ≥ 1 first-degree relative with lung 
cancer , respectively. B. Non-resectable  versus resectable  patients: 
The differences between the younger patients ≤ 65 years and older pa-
tients > 65 years are statistically significant (p = 0.0392).
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TaBlE 3
Treatment. The values are n (%).
age, yrs
≤ 55 56-65 66-75 > 75 p-valuea
Patients 29 (9.2) 82 (26.3) 121 (38.8) 80 (25.6) < 0.0001
Surgery   6 (20.7) 16 (19.5)   24 (19.8) 16 (20) 1.0000
Lobectomy   6 (20.7) 10 (12.2)   15 (12.4) 11 (13.8) 0.7310
Segment/wedge resection   0 (0)   4 (4.9)     7 (5.8)   5 (6.3) 0.4326
Pneumonectomy   0 (0)   2 (2.4)     2 (1.7)   0 (0) 0.6179
Radiotherapy 22 (75.9) 44 (53.7)   70 (57.9) 43 (53.8) 0.6330
Chemotherapy 25 (86.2) 63 (76.8)   89 (73.6) 35 (43.8) 0.0015
Single modality treatment   8 (27.6) 24 (29.3)   55 (45.5) 44 (55) 0.0005
Combined modality treatment 21 (72.4) 50 (61)   63 (52.1) 25 (31.3) 0.0009
No treatment   0 (0)   8 (9.8)     3 (2.5) 11 (13.8) 1.0000
a) ≤ 65 vs > 65 yrs.
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tical significance was generated (Table 2). Previous ret-
rospective studies have confirmed the high rate of ad-
vanced stage disease in young patients [13-16], which 
may reflect an intrinsically more aggressive malignant 
behaviour of lung cancer in young patients, a higher inci-
dence of adenocarcinoma or simply a delayed diagnosis 
due to the low prevalence of cancer in younger popula-
tions. 
In our study, the two age groups featured a similar 
duration of predominant symptoms as well as a similar 
proportion of asymptomatic patients (Table 1). Very 
young patients ≤ 55 years were nonetheless more likely 
to be symptomatic at presentation than were elderly pa-
tients (6.9% asymptomatic patients ≤ 55 years versus 
18.8% in the age category > 75 years). This supports the 
notion that symptoms in young patients may often be 
overlooked or ascribed to benign conditions until the 
disease has reached an advanced, symptomatic stage. 
There is some evidence of certain cytochemical dif-
ferences, including a significantly higher nuclear protein 
content and nuclear-protein-to-nuclear-DNA-ratio in 
lung cancer cells obtained from young patients com-
pared with cells from elderly, indicating a higher tumour 
proliferation rate as well as lower degrees of tumour dif-
ferentiation in young patients [17, 18]. Although com-
mon sites of metastatic involvement were not specific-
ally assessed in this register study, younger patients had 
a significantly higher number of biopsies from distant 
metastatic lesions than elderly patients did (Table 2), 
which is in line with the greater prevalence of advanced 
stage disease in this age-category, but may also reflect a 
greater metastatic capacity. 
Combined-modality therapy was significantly more 
common in younger patients, whereas older patients 
were more likely to undergo single-modality therapy and 
also less likely to receive chemotherapy (Table 3). Some 
previous studies have corroborated these age-based 
treatment trends [9, 16, 19], which may relate to less co-
morbidity in younger patients and thus to better toler-
ability of anticancer treatment. 
Interestingly, there were no significant differences 
in PS when comparing the two age groups (Table 1). This 
finding may indicate a general trend towards more ag-
gressive, multimodal approaches in the younger age cat-
egories. However, as comprehensive geriatric assess-
ment adds substantial prognostic information even 
among elderly characterised by good physical and men-
tal conditions [20], PS as an isolated marker of functional 
status is perhaps too simplistic and may require supple-
mental assessments. 
limitations 
There are some important limitations to this study in-
cluding the relatively small number of patients analysed 
as well as the restriction of data to one medical centre 
which limits the generalisability of our study. However, 
despite the limited number of patients, we found sev-
eral highly significant differences between younger and 
elderly patients. Also, we had access to a wide range of 
clinical information, which is often very limited in large 
cancer registries. 
Certain variables such as pack-years and exposure 
to asbestos had missing/incomplete information. 
Nonetheless, the proportion of missing data fields was 
similar across the age groups studied (p = 0.8101).
The difficulty in comparing the results with those of 
former studies lies in the variability of age cutoffs used 
to define “young” populations. For the present study,  
65 years of age was selected as it represents the normal 
age of retirement in Denmark, and thus a reasonable 
cutoff between younger and elderly patients. 
cOnclUsiOns
The present study confirms that lung cancer in younger 
patients is characterised by female overrepresentation, 
higher frequency of familial cancer aggregation, less 
prevalence of squamous cell carcinoma, more advanced 
stage disease and a significantly greater likelihood of re-
ceiving multimodal therapy. 
Moreover, since a higher proportion of the young-
est patients ≤ 55 years tended to be symptomatic at  
diagnosis, it is paramount to consider lung cancer as a 
possible diagnosis in younger patients presenting with 
symptoms that are consistent with lung disease. Also, 
early genetic background assessments should be in-
cluded when evaluating young smokers or young/mid-
dle-aged, symptomatic patients.
These contemplations are important, especially 
since younger patients, as demonstrated in our study, 
often present with late-stage, advanced disease. 
cORREsPOndEncE: Poul Henning Madsen.  
E-mail: poul.henning.madsen@rsyd.dk
accEPTEd: 7 April 2016
cOnFlicTs OF inTEREsT: Disclosure forms provided by the authors are 
available with the full text of this article at www.danmedj.dk 
In the article Dan Med J 2016;63(7):A5248 there has been the following cor-
rection on 11 July 2016. 
The explanation for Figure 1B has been changed to:  
Non-resectable   versus resectable   patients.
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